Filed to:aducanumab
alzheimers diseasebiogenclinical trialfederal assistance in the united statesfood and drug administrationhealth medical pharmahealthcare reform in the united statesjanet woodcockkaiser family foundationkatie porterlife sciencesmedicaidmedicarepresidency of lyndon b johnsonsam gandythe centers for medicare and medicaid services
Photo: Matthew Simmons, Getty Images
Parts of the medical world are continuing to rebel against Aduhelm, the controversial treatment developed by Biogen and recently approved for Alzheimer’s disease by the U.S. Food and Drug Administration. This week, two major medical centres in the U.S. said that they would not treat their patients with the drug.
The Cleveland Clinic, as first reported by the New York Times yesterday, assembled a formal panel of experts to review the evidence behind aducanumab, the active ingredient of Aduhelm, before coming to their decision.